Monopar Therapeutics Inc. (MNPR)
NASDAQ: MNPR · IEX Real-Time Price · USD
0.620
-0.055 (-8.13%)
Jul 22, 2024, 10:26 AM EDT - Market open
Monopar Therapeutics Employees
As of December 31, 2023, Monopar Therapeutics had 10 total employees, including 9 full-time and 1 part-time employees. The number of employees decreased by 2 or -16.67% compared to the previous year.
Employees
10
Change (1Y)
-2
Growth (1Y)
-16.67%
Revenue / Employee
n/a
Profits / Employee
-$760,887
Market Cap
10.89M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Novo Integrated Sciences | 230 |
Ontrak | 104 |
Check-Cap | 85 |
RedHill Biopharma | 53 |
Calidi Biotherapeutics | 41 |
Aptose Biosciences | 36 |
Lumos Pharma | 33 |
BioRestorative Therapies | 11 |
MNPR News
- 27 days ago - Monopar Announces MNPR-101-RIT Abstract Accepted as a Top-Rated Oral Presentation at EANM'24 - GlobeNewsWire
- 5 weeks ago - Monopar and NorthStar Amend & Extend Collaboration - GlobeNewsWire
- 6 weeks ago - Monopar Presents Data Showcasing the Appeal of uPAR as a Radiopharma Cancer Target and of its lead Clinical Program at the 2024 SNMMI Annual Meeting - GlobeNewsWire
- 2 months ago - Monopar Announces CFO Succession - GlobeNewsWire
- 2 months ago - Monopar Therapeutics Reports First Quarter 2024 Financial Results and Strategic Focus on its Radiopharma Pipeline - GlobeNewsWire
- 3 months ago - Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting - GlobeNewsWire
- 3 months ago - Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients - GlobeNewsWire
- 4 months ago - Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Developments - GlobeNewsWire